Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168165 | 1.00 | CHRNA7 (0.42) | CHRNA7CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL2496607 | 1.00 | CHRNA7 (0.42) | CHRNA7CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL7445339 | 0.88 | — | — | |
| SCHEMBL5049107 | 0.75 | CHRM2 (0.44) | CHRNA7CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3321470 | 0.75 | CHRM2 (0.31) | CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3317402 | 0.73 | CHRM2 (0.34) | CHRNA7CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL9049373 | 0.73 | CHRM2 (0.34) | CHRNA7CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3834021 | 0.65 | CHRNA4 (0.39) | CHRNA7CHRM2CHRM1CHRM4CHRM3 | |
| Bromide SCHEMBL7114503 | 0.63 | CHRNA7 (0.94) | CHRNA7CHRM2CHRM1CHRM4CHRM3 | |
| Bromide SCHEMBL7114497 | 0.63 | CHRNA7 (0.94) | CHRNA7CHRM2CHRM1CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025077825-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS | FAUNA BIO INCORPORATED (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-3673906-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180325878-A1 | N-BIARYLAMIDES | BAYER IP GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| EP-2440557-B1 | NOVEL STERICALLY HINDERED AMINE LIGHT STABILIZERS | BASF SE (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-4937239-A | Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents | WARNER-LAMBERT COMPANY (US) | 1990-06-26 | — | — | US | disclosed |
| EP-0366304-A2 | Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0363085-A2 | Novel compounds | BEECHAM GROUP PLC (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0338723-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1989-10-25 | — | — | EP | disclosed |
| US-4853376-A | Benzamides and benzoates having anti-emetic activity | BEECHAM GROUP, P.L.C. (GB) | 1989-08-01 | — | — | US | disclosed |
| EP-0322182-A2 | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1989-06-28 | — | — | EP | disclosed |
| EP-0261763-A1 | Novel bridged bicyclic N-heterocycles | BEECHAM GROUP PLC (GB) | 1988-03-30 | — | — | EP | disclosed |
| EP-0239309-A2 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1987-09-30 | — | — | EP | disclosed |
| EP-0221702-A2 | Quinolidine derivatives | BEECHAM GROUP PLC (GB) | 1987-05-13 | — | — | EP | disclosed |
| US-4292190-A | ANTIFREEZES FOR COOLING SYSTEMS OF INTERNAL COMBUSTION ENGINES | BASF WYANDOTTE CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRNA7 4678/4885CHRM2 4876/4885CHRM1 4878/4885 |
| US-20180325878-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | CHRNA7 190/4885CHRM2 479/4885CHRM1 919/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | CHRNA7 190/4885CHRM2 479/4885CHRM1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.